發(fā)布時(shí)間：2017-12-28 14:33

  本文關(guān)鍵詞：浙江省2010～2014年甲型肝炎疫苗疑似預(yù)防接種異常反應(yīng)監(jiān)測分析　出處：《中國疫苗和免疫》2015年06期 　論文類型：期刊論文

  更多相關(guān)文章： 甲型肝炎疫苗 疑似預(yù)防接種異常反應(yīng) 監(jiān)測

【摘要】：目的分析浙江省2010~2014年甲型肝炎(甲肝)減毒活疫苗(HepA-L)和甲肝滅活疫苗(HepA-I)的疑似預(yù)防接種異常反應(yīng)(adverse events following immunization,AEFI)監(jiān)測資料,了解甲肝疫苗AEFI發(fā)生和分布情況,初步探討其預(yù)防接種安全性。方法通過中國AEFI信息管理系統(tǒng)和浙江省免疫規(guī)劃信息系統(tǒng)獲取AEFI監(jiān)測數(shù)據(jù)及接種數(shù)據(jù),對(duì)HepA-L和HepA-I的AEFI發(fā)生情況進(jìn)行分析。結(jié)果 2010~2014年浙江省HepA-L AEFI報(bào)告395例,男女性別比為2.0∶1,7歲者占99.49%,報(bào)告縣(區(qū))比例為87.8%;HepA-I AEFI報(bào)告108例,男女性別比為1.3∶1,7歲者占96.30%,報(bào)告縣(區(qū))比例為45.6%;兩種疫苗AEFI報(bào)告均以第2、3季度居多。HepA-L AEFI報(bào)告發(fā)生率為14.39/10萬劑,一般反應(yīng)為9.98/10萬劑,異常反應(yīng)為3.71/10萬劑;HepA-I AEFI報(bào)告發(fā)生率為9.72/10萬劑,一般反應(yīng)為7.74/10萬劑,異常反應(yīng)為1.71/10萬劑。HepA-L和HepA-I AEFI報(bào)告例數(shù)和報(bào)告發(fā)生率均呈現(xiàn)逐年上升趨勢。一般反應(yīng)以發(fā)熱、紅腫、硬結(jié)為主,異常反應(yīng)以過敏性皮疹為主;均主要集中在接種后≤1d發(fā)生。HepA-L和HepA-I AEFI分別有99.2%、100%治愈或好轉(zhuǎn),均無死亡報(bào)告。結(jié)論浙江省HepA-L和HepA-I的安全性均在可接受范圍內(nèi);HepA-L AEFI報(bào)告發(fā)生率稍高于HepA-I;AEFI監(jiān)測敏感性逐年提高。
[Abstract]:Objective to analyze the 2010~2014 in Zhejiang province hepatitis A (HAV) live attenuated vaccine (HepA-L) and inactivated hepatitis A vaccine (HepA-I) suspected abnormal reaction to vaccination (adverse events following immunization, AEFI) monitoring data, to understand the occurrence and distribution of hepatitis A vaccine AEFI situation, to explore the safety of vaccination. Methods the AEFI monitoring data and vaccination data were obtained through the Chinese AEFI information management system and Zhejiang immunization planning information system, and the occurrence of AEFI in HepA-L and HepA-I was analyzed. Results 395 cases of 2010~2014 in Zhejiang province HepA-L AEFI report, the sex ratio was 2 1,7 years old accounted for 99.49%, the report of the county (District) accounted for 87.8%; 108 cases of HepA-I AEFI report, the sex ratio was 1.3 1,7 years old accounted for 96.30%, the report of the county (District) accounted for 45.6%; two kinds of vaccine AEFI report the majority are in the second, third quarter. The incidence of HepA-L AEFI reports is 14.39/10 10000, the general response is 9.98/10 million, the abnormal reaction is 3.71/10 million, the incidence of HepA-I AEFI report is 9.72/10 million, the general response is 7.74/10 million, and the abnormal reaction is 1.71/10 million. The number of reports and the incidence of reports in HepA-L and HepA-I AEFI are increasing year by year. The general reaction with fever, redness, induration, abnormal reactions to allergic rash; are mainly concentrated in less than 1D after inoculation. HepA-L and HepA-I AEFI were cured or improved in 99.2%, 100%, and no deaths were reported. Conclusion the safety of HepA-L and HepA-I in Zhejiang province is acceptable. The incidence of HepA-L AEFI report is slightly higher than that of HepA-I, and the sensitivity of AEFI monitoring is increasing year by year.
【作者單位】： 浙江省疾病預(yù)防控制中心;
【分類號(hào)】：R186
【正文快照】： 甲型肝炎(甲肝)是一種主要以糞-口途徑傳播的病毒感染性疾病,潛伏期為15~50天,平均潛伏期為28天[1-3],在許多發(fā)展中國家,80%以上的青少年病毒性肝炎為甲肝病毒感染,而且在發(fā)達(dá)國家也較為常見[4-6]。目前全球使用的甲肝疫苗有兩種:甲肝滅活疫苗(Hepatitis A Inactivated Vaccin

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 秦梅,龔傳霞;預(yù)防接種異常反應(yīng)的探討[J];中國農(nóng)村衛(wèi)生事業(yè)管理;2003年05期

2 楊敏姬;預(yù)防接種異常反應(yīng)調(diào)查分析[J];浙江預(yù)防醫(yī)學(xué);2003年04期

3 張小芳,王桂琴;預(yù)防接種異常反應(yīng)的預(yù)防措施[J];齊魯醫(yī)學(xué)雜志;2004年06期

4 龐耀,黃瑩瑩;1994～2003年欽州市預(yù)防接種異常反應(yīng)個(gè)案的調(diào)查分析[J];華南預(yù)防醫(yī)學(xué);2005年01期

5 陳廷瑞;;預(yù)防接種異常反應(yīng)補(bǔ)償救濟(jì)機(jī)構(gòu)的探討[J];中國公共衛(wèi)生管理;2006年04期

6 劉燕;;預(yù)防接種異常反應(yīng)分析及處理[J];中國生育健康雜志;2007年02期

7 廖慶輝;許少山;;1996～2006年龍巖市新羅區(qū)預(yù)防接種異常反應(yīng)資料分析[J];預(yù)防醫(yī)學(xué)論壇;2007年08期

8 尚鵬輝;劉大衛(wèi);刁琳琪;鐘革;梁曉峰;;預(yù)防接種異常反應(yīng)補(bǔ)償機(jī)制態(tài)度調(diào)查分析[J];中國計(jì)劃免疫;2007年06期

9 楊瑋;帥粉榮;;常見疑似預(yù)防接種異常反應(yīng)及處理[J];延安大學(xué)學(xué)報(bào)(醫(yī)學(xué)科學(xué)版);2007年04期

10 鄭華;;預(yù)防接種異常反應(yīng)發(fā)生的因素及對(duì)策[J];實(shí)用醫(yī)技雜志;2007年22期

相關(guān)會(huì)議論文 前6條

1 張世英;;深圳市預(yù)防接種異常反應(yīng)處理工作的現(xiàn)狀、問題及對(duì)策[A];2012深圳市預(yù)防醫(yī)學(xué)會(huì)學(xué)術(shù)研討會(huì)論文匯編[C];2012年

2 張世英;;深圳市預(yù)防接種異常反應(yīng)處理工作的現(xiàn)狀、問題及對(duì)策[A];2012廣東省預(yù)防醫(yī)學(xué)會(huì)學(xué)術(shù)年會(huì)資料匯編[C];2013年

3 顧秀月;孫廣河;董慶梅;;一例接種水痘疫苗后發(fā)生疑似預(yù)防接種異常反應(yīng)死亡的調(diào)查[A];中華預(yù)防醫(yī)學(xué)會(huì)石油系統(tǒng)分會(huì)第七屆預(yù)防醫(yī)學(xué)學(xué)術(shù)交流會(huì)論文集[C];2011年

4 陸國平;李e，

本文編號(hào)：1346417